Objectives
This study aims to examine the association between migraine, major depressive disorder (MDD), and generalized anxiety disorder (GAD) in adolescents and young adults.
Background
MDD, GAD, and migraine are often comorbid, with adult migraineurs having twice the rate of MDD as nonmigraineurs and more disabling migraines. Findings in children are less consistent; but anxiety disorders, including GAD, are prevalent among youth. Data on the association between MDD, GAD and migraine in adolescents and young adults are sparse.
Methods
Participants (N=227), between 15 and 20 years old, who were unmedicated or within one month of beginning antidepressant treatment underwent a comprehensive assessment to establish the presence of MDD and GAD, according to the Diagnostic & Statistical Manual, Fourth Edition, Text Revision, and to rate their symptom severity using the Longitudinal Interval Follow-up Evaluation for Adolescents. They then completed the ID Migraine. The Student’s t test and chi-square test were used to compare continuous and categorical variables, respectively, across participants with vs. without migraine. Logistic regression analysis examined the association between the presence of migraine and psychopathology.
Results
A diagnosis of MDD was associated with significantly increased risk of having migraine. Moreover, more severe and persistent ratings of depression were associated with an even higher likelihood of having migraine. A diagnosis of GAD was also significantly associated with the presence of migraine. The prevalence of comorbid MDD and GAD was significantly higher in participants with migraine than in those without migraine (55% vs. 22%, p<0.0001). When examined concurrently, GAD remained significantly associated with migraine, with a statistical trend for MDD to be associated with it. The use of selective serotonin reuptake inhibitors did not significantly alter these findings and serum vitamin D concentration was not associated with any of the disorders.
Conclusions
The comorbidity of migraine, MDD, and GAD has important clinical and research implications. Shared psychological and biological vulnerabilities may be involved in the three conditions. Greater understanding of the shared vulnerabilities can lead to unified treatments.
ClinicalTrials.gov Identifier
NCT02147184